Manhattan Pharmaceuticals doses first group in obesity trial

By Elaine Rigoli

Tampa, Fla., June 29 - Manhattan Pharmaceuticals, Inc. has started dosing the first group of patients in its phase 2a clinical trial of oral Oleoyl-estrone (OE), the company's novel drug candidate for the treatment of obesity.

The randomized, double-blind, placebo-controlled, parallel group phase 2a study of OE is designed to evaluate the safety, preliminary efficacy and pharmacokinetics of two 14-day cycles of escalating oral doses of the compound in obese adult subjects.

Dose levels of OE will be placebo, 5, 10 and 20 mg daily, according to a news release.

Manhattan expects that 100 subjects will be randomly enrolled into one of these four treatment groups that comprise this phase 2a trial.

In addition to safety and tolerability, the study is also designed to further evaluate weight loss, maintenance of weight loss and other therapeutic outcomes.

Patient recruitment is ongoing, the release said.

Manhattan Pharmaceuticals, a development-stage pharmaceutical company, is located in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.